Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | FPR1 | P21462 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496056 | 0.86 | MAPKAPK2 (0.66) | MAPKAPK2LMNAMAPTKCNH2HIF1A | |
| SCHEMBL6500327 | 0.80 | NR1H2 (0.45) | MAPKAPK2MCHR1MAPTTRPV1KCNH2 | |
| SCHEMBL6680389 | 0.79 | MAPKAPK2 (0.46) | MAPKAPK2FPR1FPR2LMNAMAPT | |
| SCHEMBL6490778 | 0.78 | MAPKAPK2 (0.46) | MAPKAPK2LMNAMAPTKCNH2HIF1A | |
| SCHEMBL6490755 | 0.77 | CA1 (0.51) | MAPKAPK2LMNAMAPTKCNH2HIF1A | |
| SCHEMBL6496929 | 0.77 | MAPT (0.57) | MAPKAPK2LMNAMAPT | |
| SCHEMBL6501481 | 0.77 | CA1 (0.52) | MAPKAPK2LMNAMAPTKCNH2HIF1A | |
| SCHEMBL6677499 | 0.76 | NPC1 (0.50) | LMNATRPV1HIF1AEPAS1 | |
| SCHEMBL6490282 | 0.76 | AR (0.45) | MAPKAPK2KCNH2HIF1AEPAS1 | |
| SCHEMBL12153158 | 0.76 | NOTUM (0.49) | MLNRMAPTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | MAPKAPK2 3154/4885MCHR1 3592/4885MLNR 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.